ATE1: Versatile Protein with Broad Application Prospects (G11101)

Target Name: ATE1

NCBI ID: G11101

ATE1: Versatile Protein with Broad Application Prospects

ATE1 (Arginyl-tRNA-protein transferase) is a protein that plays a critical role in the transfer of amino acids from the tRNA to the protein during translation of mRNA in eukaryotic cells. Mutations in the ATE1 gene have been linked to various diseases, including Box splicing abnormalities, splin-dependent neurological disorders, and thrombocytopenic purpura, among others. In recent years, researchers have conducted in-depth studies on ATE1 and found that it has broad application prospects in drug discovery and biomarkers.

First, the role of ATE1 in drug discovery. Mutations in ATE1 can cause changes in the protein structure, thereby affecting its function. Many drugs work by interfering with the function of ATE1 to exert their therapeutic effects. For example, gemcitabine is a chemotherapy drug used to treat Hodgkin lymphoma. Its mechanism of action is to interfere with protein synthesis in cancer cells by inhibiting the function of ATE1. In addition, some anti-malarial drugs, such as chloroquine and mechloroquine, have also been found to inhibit the function of ATE1, thereby blocking protein synthesis by the Plasmodium parasite.

Secondly, the role of ATE1 in biomarkers. Biomarkers are molecules or cells that can be used to detect and track disease or drug status. ATE1, as a protein, can serve as a biomarker to detect and track disease progression. For example, some studies have shown that the expression level of ATE1 can serve as a biomarker for Parkinson's disease. In addition, mutations in ATE1 have also been found in some neurological diseases, such as splin-dependent neurological diseases, and therefore can be used as biomarkers for these diseases.

In addition, the role of ATE1 in drug screening has also been widely used. Since mutations in ATE1 can lead to the loss of its function, ATE1 can be used as a target for drug screening to screen out compounds with therapeutic effects. For example, some studies have shown that mutations in ATE1 can be used as targets for drug screening to screen compounds with anti-neurodegenerative disease effects.

In summary, ATE1, as a protein, has broad application prospects in drug discovery, biomarkers, and drug screening. As technology continues to advance, our research on ATE1 will also be in-depth

Protein Name: Arginyltransferase 1

Functions: Involved in the post-translational conjugation of arginine to the N-terminal aspartate or glutamate of a protein. This arginylation is required for degradation of the protein via the ubiquitin pathway. Does not arginylate cysteine residues (By similarity)

More Common Targets